RELATED STUDY
A CB2-Selective Cannabinoid Suppresses T-cell Activities and Increases Tregs and IL-10
Key Findings: This study of the CB2-selective agonists O-1966, using Mixed Lymphocyte Reaction (MLR) on mice spleen cells as a model of transplant rejection, found that the compound effectively prevented or delayed graft rejection and presents a potential novel therapeutic target in graft-versus-host disease in transplant recipients.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): United States
Year of Pub: 2016
Cannabinoids Studied: Tetrahydrocannabinol (THC), O-x Synthetic Cannabinoids, Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Ligands Studied: Anti-inflammatory cytokines
Dosage: O-1966 (8 to 32 μM)
Route of Administration: In vitro
Citation: Robinson RH, et al. A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10. J Neuroimmune Pharmacol. 2015; 10:318-32. doi: 10.1007/s11481-015-9611-3
Authors: Robinson RH, Meissler JJ, Fan X, Yu D, Adler MW, Eisenstein TK
